This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Marc Poulin, University of Calgary
ClinicalTrials.gov Identifier:
NCT01280006
First received: January 18, 2011
Last updated: December 2, 2011
Last verified: December 2011
  Purpose
The study has been designed to assess the effect of cyclooxygenase inhibition on blood pressure, cerebral blood flow, ventilation and renal hemodynamics following chronic intermittent hypoxia exposure.

Condition Intervention Phase
Obstructive Sleep Apnea Hypertension Cardiovascular Diseases Stroke Other: Intermittent hypoxia Drug: Indomethacin Drug: Celecoxib Drug: Placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans

Resource links provided by NLM:


Further study details as provided by Marc Poulin, University of Calgary:

Primary Outcome Measures:
  • Arterial Blood Pressure [ Time Frame: Six weeks ]
    Blood pressure will be monitored during all three protocols.

  • Cerebral Blood Flow [ Time Frame: Six weeks ]
    The cerebral blood flow will be mesauresed during each testing days of all three protocols.


Secondary Outcome Measures:
  • Ventilatory Response [ Time Frame: Six weeks. ]
    The ventilatory response will be measured during each testing days of all three protocols.

  • Renal Hemodynamics [ Time Frame: Six weeks ]
    The renal hemodynamics will be measured during each testing days of all three protocols.


Enrollment: 12
Study Start Date: January 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Intermittent hypoxia
    The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
    Drug: Indomethacin

    The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.

    Indomethacin: 50 mg, Oral, three times per day for five days.

    Other Name: Apo-Indomethacin
    Drug: Celecoxib

    The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.

    Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses.

    Other Name: Celebrex
    Drug: Placebo

    The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.

    Placebo: Oral, three times per day for five days.

Detailed Description:

The study will specifically evaluate:

  1. Cardiovascular effect of cyclooxygenase inhibitors on cerebral, vascular, blood pressure and homeostatic responses following chronic intermittent hypoxia exposure.
  2. Ventilatory response of cyclooxygenase inhibitors following chronic intermittent hypoxia exposure
  3. Evaluate the renal hemodynamic effect of chronic intermittent hypoxia exposure and cyclooxygenase inhibition.
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male subjects
  • 18 - 45 years of age
  • Informed written consent

Exclusion Criteria:

  • Any history of cardio-respiratory diseases, ongoing medication, smoking, trauma, acute illnesses, collagen vascular diseases, rheumatoid arthritis, osteoarthritis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01280006

Locations
Canada, Alberta
The Laboratory of Human Cerebrovascular Physiology, HMRB 209 & HMRB 230, University of Calgary
Calgary, Alberta, Canada, T2N 4N1
Sponsors and Collaborators
University of Calgary
Investigators
Principal Investigator: Marc J Poulin, PhD University of Calgary
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Marc Poulin, Prof Dr., University of Calgary
ClinicalTrials.gov Identifier: NCT01280006     History of Changes
Other Study ID Numbers: UC-MMHAP-COX-IH-2010001
Study First Received: January 18, 2011
Last Updated: December 2, 2011

Keywords provided by Marc Poulin, University of Calgary:
Hypoxia
Brain
Cerebral Blood Flow
Obstructive Sleep Apnea
Sleep
Blood Pressure
Hypertension
Myocardial Infarction
Stroke
Ventilation
Renal Blood Flow

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Anoxia
Vascular Diseases
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Indomethacin
Celecoxib
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Tocolytic Agents
Reproductive Control Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on June 23, 2017